MedTrace Logo

Study to Evaluate the Mass Balance and Biotransformation of [14C]SHR1459 in Healthy Adult Male Volunteers

NCT05095337 · Status: UNKNOWN · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 6

Last updated 2022-07-01

No results posted yet for this study

Summary

Evaluate the Mass Balance and Biotransformation of \[14C\]SHR1459 in Healthy Adult Male Volunteers

Conditions

  • Healthy Adult Male Volunteers

Interventions

DRUG

[14C]SHR1459

Patients will receive single dose of orally \[14C\]SHR1459 on Day 1.

Sponsors & Collaborators

  • Jiangsu HengRui Medicine Co., Ltd.

    lead INDUSTRY

Study Design

Allocation
NA
Purpose
OTHER
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
45 Years
Sex
MALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2022-06-07
Primary Completion
2022-07-05
Completion
2022-07-25

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05095337 on ClinicalTrials.gov